BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park Y, Kim SH, Kim SH, Jeon YH, Lee J, Kim MJ, Choi D, Lee WJ, Kim H, Koo JH, Lim HK. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience. Korean J Radiol 2010;11:433-40. [PMID: 20592927 DOI: 10.3348/kjr.2010.11.4.433] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Hope TA, Fowler KJ, Sirlin CB, Costa EAC, Yee J, Yeh BM, Heiken JP. Hepatobiliary agents and their role in LI-RADS. Abdom Imaging 2015;40:613-25. [DOI: 10.1007/s00261-014-0227-5] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 10.1] [Reference Citation Analysis]
2 Fowler KJ, Brown JJ, Narra VR. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis. Hepatology. 2011;54:2227-2237. [PMID: 21932400 DOI: 10.1002/hep.24679] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 7.1] [Reference Citation Analysis]
3 Lebedis C, Luna A, Soto JA. Use of magnetic resonance imaging contrast agents in the liver and biliary tract. Magn Reson Imaging Clin N Am 2012;20:715-37. [PMID: 23088947 DOI: 10.1016/j.mric.2012.07.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
4 Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL. Diagnostic Challenges and Pitfalls in MR Imaging with Hepatocyte-specific Contrast Agents. RadioGraphics 2011;31:1547-68. [DOI: 10.1148/rg.316115528] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 7.7] [Reference Citation Analysis]
5 Cerny M, Chernyak V, Olivié D, Billiard J, Murphy-lavallée J, Kielar AZ, Elsayes KM, Bourque L, Hooker JC, Sirlin CB, Tang A. LI-RADS Version 2018 Ancillary Features at MRI. RadioGraphics 2018;38:1973-2001. [DOI: 10.1148/rg.2018180052] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
6 Baird AJ, Amos GJ, Saad NF, Benson MD. Retrospective audit to determine the diagnostic accuracy of Primovist-enhanced MRI in the detection of hepatocellular carcinoma in cirrhosis with explant histopathology correlation. J Med Imaging Radiat Oncol 2013;57:314-20. [PMID: 23721140 DOI: 10.1111/1754-9485.12038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
7 Jang KM, Kim SH, Kim YK, Park MJ, Lee MH, Hwang J, Rhim H. Imaging features of small (≤3 cm) pancreatic solid tumors on gadoxetic-acid-enhanced MR imaging and diffusion-weighted imaging: an initial experience. Magnetic Resonance Imaging 2012;30:916-25. [DOI: 10.1016/j.mri.2012.02.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
8 Besa C, Kakite S, Cooper N, Facciuto M, Taouli B. Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T. Acta Radiol Open 2015;4:2047981614561285. [PMID: 25793110 DOI: 10.1177/2047981614561285] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
9 Cortis K, Liotta R, Miraglia R, Caruso S, Tuzzolino F, Luca A. Incorporating the hepatobiliary phase of gadobenate dimeglumine-enhanced MRI in the diagnosis of hepatocellular carcinoma: increasing the sensitivity without compromising specificity. Acta Radiol 2016;57:923-31. [DOI: 10.1177/0284185115616291] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kim EH, Oh JS, Chun HJ, Choi BG, Lee HG. Usefulness of fusion images of unenhanced and contrast-enhanced arterial phase cone-beam CT in the detection of viable hepatocellular carcinoma during transarterial chemoembolization. Diagn Interv Radiol 2018;24:262-7. [PMID: 30211679 DOI: 10.5152/dir.2018.17503] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014;273:30-50. [PMID: 25247563 DOI: 10.1148/radiol.14132362] [Cited by in Crossref: 256] [Cited by in F6Publishing: 208] [Article Influence: 36.6] [Reference Citation Analysis]
12 Joo I, Choi BI. New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer. 2012;1:94-109. [PMID: 24159577 DOI: 10.1159/000342404] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
13 Cannella R, Brancatelli G, Rangaswamy B, Minervini MI, Borhani AA, Furlan A. Enhancement pattern of hepatocellular adenoma (HCA) on MR imaging performed with Gd-EOB-DTPA versus other Gd-based contrast agents (GBCAs): An intraindividual comparison. Eur J Radiol 2019;119:108633. [PMID: 31437747 DOI: 10.1016/j.ejrad.2019.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Jhaveri K, Cleary S, Audet P, Balaa F, Bhayana D, Burak K, Chang S, Dixon E, Haider M, Molinari M, Reinhold C, Sherman M. Consensus Statements From a Multidisciplinary Expert Panel on the Utilization and Application of a Liver-Specific MRI Contrast Agent (Gadoxetic Acid). American Journal of Roentgenology 2015;204:498-509. [DOI: 10.2214/ajr.13.12399] [Cited by in Crossref: 57] [Cited by in F6Publishing: 19] [Article Influence: 8.1] [Reference Citation Analysis]
15 Tang A, Mcinnes M, Hope TA, Vu K, Amre D, Wolfson T, Roy C, Mâsse BR, Sirlin C; Cochrane Hepato-Biliary Group. Magnetic resonance imaging performed with gadoxetate disodium for the diagnosis of hepatocellular carcinoma in cirrhotic and non-cirrhotic patients. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012766] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
16 Chanyaputhipong J, Low SC, Chow PK. Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians. Int J Hepatol. 2011;2011:489342. [PMID: 21994860 DOI: 10.4061/2011/489342] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
17 Vanhooymissen IJ, Thomeer MG, Braun LM, Gest B, van Koeverden S, Willemssen FE, Hunink M, De Man RA, Ijzermans JN, Dwarkasing RS. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia: Hepatobiliary Phase of Two Contrast Agents. J Magn Reson Imaging 2019;49:700-10. [DOI: 10.1002/jmri.26227] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
18 Luna A, Pahwa S, Bonini C, Alcalá-Mata L, Wright KL, Gulani V. Multiparametric MR Imaging in Abdominal Malignancies. Magn Reson Imaging Clin N Am 2016;24:157-86. [PMID: 26613880 DOI: 10.1016/j.mric.2015.08.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
19 Erra P, Puglia M, Ragozzino A, Maurea S, Liuzzi R, Sabino G, Barbuto L, Cuocolo A, Imbriaco M. Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review. Radiol Med. 2015;120:1002-1011. [PMID: 25900253 DOI: 10.1007/s11547-015-0539-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
20 Lee KH, Lee JM, Park JH, Kim JH, Park HS, Yu MH, Yoon JH, Han JK, Choi BI. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid. Korean J Radiol. 2013;14:894-904. [PMID: 24265564 DOI: 10.3348/kjr.2013.14.6.894] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
21 Liu X, Zou L, Liu F, Zhou Y, Song B. Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e70896. [PMID: 23967130 DOI: 10.1371/journal.pone.0070896] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
22 Zhao X, Huang M, Zhu Q, Wang T, Liu Q. The relationship between liver function and liver parenchymal contrast enhancement on Gd-BOPTA-enhanced MR imaging in the hepatocyte phase. Magnetic Resonance Imaging 2015;33:768-73. [DOI: 10.1016/j.mri.2015.03.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
23 Hwang J, Kim SH, Lee MW, Lee JY. Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT. Br J Radiol 2012;85:e314-22. [PMID: 22167508 DOI: 10.1259/bjr/27727228] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
24 Schraml C, Kaufmann S, Rempp H, Syha R, Ketelsen D, Notohamiprodjo M, Nikolaou K. Imaging of HCC-Current State of the Art. Diagnostics (Basel). 2015;5:513-545. [PMID: 26854169 DOI: 10.3390/diagnostics5040513] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
25 Van Wettere M, Paulatto L, Raynaud L, Bruno O, Payancé A, Plessier A, Rautou PE, Paradis V, Cazals-Hatem D, Valla D, Vilgrain V, Ronot M. Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome. JHEP Rep 2020;2:100097. [PMID: 32435753 DOI: 10.1016/j.jhepr.2020.100097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lee DH, Lee JM, Klotz E, Kim SJ, Kim KW, Han JK, Choi BI. Detection of recurrent hepatocellular carcinoma in cirrhotic liver after transcatheter arterial chemoembolization: value of quantitative color mapping of the arterial enhancement fraction of the liver. Korean J Radiol 2013;14:51-60. [PMID: 23323031 DOI: 10.3348/kjr.2013.14.1.51] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
27 Guthrie JA. Cirrhosis and focal liver lesions: MRI findings. Imaging 2013;22:68887955. [DOI: 10.1259/imaging/68887955] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Li Y, Chen J, Weng S, Yan C, Ye R, Zhu Y, Wen L, Cao D, Hong J. Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma. Ann Transl Med 2021;9:55. [PMID: 33553348 DOI: 10.21037/atm.2020.02.38] [Reference Citation Analysis]
29 Vernuccio F, Bruno A, Costanzo V, Bartolotta TV, Vieni S, Midiri M, Salvaggio G, Brancatelli G. Comparison of the Enhancement Pattern of Hepatic Hemangioma on Magnetic Resonance Imaging Performed With Gd-EOB-DTPA Versus Gd-BOPTA. Curr Probl Diagn Radiol 2020;49:398-403. [PMID: 31253462 DOI: 10.1067/j.cpradiol.2019.06.006] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Miura T, Ban D, Tanaka S, Mogushi K, Kudo A, Matsumura S, Mitsunori Y, Ochiai T, Tanaka H, Tanabe M. Distinct clinicopathological phenotype of hepatocellular carcinoma with ethoxybenzyl-magnetic resonance imaging hyperintensity: association with gene expression signature. Am J Surg. 2015;210:561-569. [PMID: 26105803 DOI: 10.1016/j.amjsurg.2015.03.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
31 Husarik DB, Gupta RT, Ringe KI, Boll DT, Merkle EM. Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents. Acad Radiol 2011;18:1549-54. [PMID: 21958599 DOI: 10.1016/j.acra.2011.08.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
32 Liu X, Zou L, Liu F, Zhou Y, Song B. Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e70896. [PMID: 23967130 DOI: 10.1371/journal.pone.0070896.ecolletion] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Sirlin CB, Hussain HK, Jonas E, Kanematsu M, Min Lee J, Merkle EM, Peck-Radosavljevic M, Reeder SB, Ricke J, Sakamoto M. Consensus report from the 6th International forum for liver MRI using gadoxetic acid. J Magn Reson Imaging. 2014;40:516-529. [PMID: 24923695 DOI: 10.1002/jmri.24419] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
34 Tan CH, Low SC, Thng CH. APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. Int J Hepatol. 2011;2011:519783. [PMID: 22007313 DOI: 10.4061/2011/519783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
35 Chou CT, Chen YL, Wu HK, Chen RC. Characterization of hyperintense nodules on precontrast T1-weighted MRI: utility of gadoxetic acid-enhanced hepatocyte-phase imaging. J Magn Reson Imaging. 2011;33:625-632. [PMID: 21563246 DOI: 10.1002/jmri.22500] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
36 Neri E, Bali MA, Ba-Ssalamah A, Boraschi P, Brancatelli G, Alves FC, Grazioli L, Helmberger T, Lee JM, Manfredi R. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol. 2016;26:921-931. [PMID: 26194455 DOI: 10.1007/s00330-015-3900-3] [Cited by in Crossref: 90] [Cited by in F6Publishing: 73] [Article Influence: 12.9] [Reference Citation Analysis]